New combo therapy aims to control blood cancer
NCT ID NCT03609593
Summary
This study tested a 15-month treatment plan for adults newly diagnosed with chronic lymphocytic leukemia (CLL), a type of blood cancer. It combined three drugs: bendamustine and rituximab given first, followed by a year of the pill venetoclax. The goal was to see how well this sequence reduces cancer levels and controls the disease, while carefully managing potential side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.